Impact of the oxytocin receptor antagonist (ATOSIBAN) administered shortly before embryo transfer on pregnancy outcome after intracytoplasmic sperm injection (ICSI)

Hebisha, S.A.; Aboelazm, B.A.; Adel, H.M.; Ahmed, A.I.

doi:10.1016/j.fertnstert.2016.07.260

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Seven studies were considered in the synthesis, including 3 observational studies ( Chou et al ., 2011 ; He et al ., 2016b ; Lan et al ., 2012 ) and 4 randomized controlled trials ( He et al ., 2016a ; Hebisha et al ., 2016 ; Moraloglu et al ., 2010 ; Ng et al ., 2014 ). The characteristics of the included trials are shown in Table 1 .…”

Section: Resultsmentioning

confidence: 99%

“…The intervention included the administration of a single bolus dose ( Chou et al ., 2011 ; Hebisha et al ., 2016 ; He et al ., 2016a ; b ) prior to the embryo transfer, or the administration of a bolus doses plus maintaining a continues dose ( Lan et al ., 2012 ; Moraloglu et al ., 2010 ; Ng et al ., 2014 ).…”

Section: Resultsmentioning

confidence: 99%

“…The outcomes evaluated included implantation rate ( Chou et al ., 2011 ; He et al ., 2016a ; Lan et al ., 2012 ; Moraloglu et al ., 2010 ), clinical pregnancy rate ( He et al ., 2016;b ; Lan et al ., 2012 ; Moraloglu et al ., 2010 ; Chou et al ., 2011 ; Hebisha et al ., 2016 ) and delivery rate ( Chou et al ., 2011 ; Ng et al ., 2014 ).…”

Section: Resultsmentioning

confidence: 99%

“…Atosiban was administered to inhibit uterine contractions ( He et al ., 2016a ; Hebisha et al ., 2016 ). Atosiban is a uterine-specific, mixed vasopressin V1-a and oxytocin-receptor antagonist, that is registered for tocolysis in imminent premature birth.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Atosiban improves the outcome of embryo transfer. A systematic review and meta-analysis of randomized and non-randomized trials

Schwarze¹,

Crosby²,

Mackenna³

2020

JBRA Assisted Reproduction

View full text Add to dashboard Cite

Objective: To estimate the effectiveness of Atosiban in improving the outcome after embryo transfer. The effectiveness of embryo transfer per cycle is still relatively low. One possible explanation might be uterine contractility that expels the transferred embryos. Atosiban improved the outcome of embryo transfer by reducing uterine contractility. Methods: Data sources: A systematic review of papers in English using MEDLINE and EMBASE (1990-2019). Search terms included Atosiban, embryo transfer. Study selection: We included studies that compared the outcomes of embryo transfer with Atosiban and a control group. Data Extracting: Independent extraction of papers by two authors, using predefined data fields, including study quality indicators. Results: All pooled analyses were based on a fixed-effect model. Four randomised controlled trials, including 1,025 women, and two non-randomised trials, including 686 patients, met our inclusion criteria. In both studies, the heterogeneity was moderate. Atosiban increased clinical pregnancy rates regardless of the indication for ART or type of embryo transferred. Pooled OR in randomized controlled trials reached 1.47 (1.18-1.82), and in non-randomised controlled trials it reached 1.50 (95% CI 1.10-2.05) Conclusion: Atosiban appears to increase the clinical pregnancy rates in women undergoing embryo transfer.

show abstract